drugset / Trial / NCT05395533
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NaSingle-groupOpen-labelTreatment
Summary
This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.
Timeline
- Start
- 2020-09-08
- Primary completion
- 2025-07-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRS005 | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | TRS005 | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | TRS005 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | TRS005 | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | TRS005 | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Subject | TRS005 | Monoclonal antibody | 2.1 mg/kg | Intravenous |